Publikationen

104.

Dietary glycocalyx mimetic reduces vascular risk in Type 2 diabetes: evidence from urinary peptidomic classifiers in a South-Asian Surinamese Cohort.

Biglari S, Yuan L, Mischak H, Siwy J, Latosinska A, Banasik M, van den Berg BM.

Diabetes Res Clin Pract. 2025 Nov;229:112931. doi: 10.1016/j.diabres.2025.112931.

103.

In silico prediction of optimal multifactorial intervention in chronic kidney disease.

Latosinska A, Mina IK, Nguyen TMN, Golovko I, Keller F, Mayer G, Rossing P, Staessen JA, Delles C, Beige J, Glorieux G, Clark AL, Schanstra JP, Vlahou A, Peter K, Rychlík I, Ortiz A, Campbell A, Rupprecht H, Persson F, Mischak H, Siwy J.

J Transl Med. 2025 Aug 21;23(1):943. doi: 10.1186/s12967-025-06977-3.

102.

The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention?

Biglari S, Mischak H, Beige J, Latosinska A, Siwy J, Banasik M.

Biomolecules. 2025 Jun 3;15(6):809. doi: 10.3390/biom15060809.

101.

Association of Urinary Collagen Type III Degradation Product With Kidney Function and Fibrosis in Chronic Kidney Disease Patients.

Martin EM, Genovese F, Mischak H, Siwy J, Rupprecht H, Catanese L, Latosinska A.

Proteomics. 2025 Jun;25(11-12):e202400354. doi: 10.1002/pmic.202400354.

100.

Differential risk assessment in persons at risk of type 2 diabetes using urinary peptidomics.

Schork A, Fritsche A, Schleicher ED, Peter A, Heni M, Stefan N, von Schwartzenberg RJ, Guthoff M, Mischak H, Siwy J, Birkenfeld AL, Wagner R.

Metabolism. 2025 Jun;167:156174. doi: 10.1016/j.metabol.2025.156174.

99.

Investigation of the Urinary Peptidome to Unravel Collagen Degradation in Health and Kidney Disease.

Mina IK, Iglesias-Martinez LF, Ley M, Fillinger L, Perco P, Siwy J, Mischak H, Jankowski V.

Proteomics. 2025 Jun;25(11-12):e202400279. doi: 10.1002/pmic.202400279.

98.

Urinary peptide signature distinguishes autosomal recessive polycystic kidney disease from other causes of chronic kidney disease.

Burgmaier K, Buffin-Meyer B, Klein J, Becknell B, McLeod D, Boeckhaus J, Gross O, Dafinger C, Siwy J, Decramer S, Schaefer F, Liebau MC, Schanstra JP.

Clin Kidney J. 2025 Apr 15;18(5):sfaf093. doi: 10.1093/ckj/sfaf093.

97.

Racial and regional disparities in the risk of noncommunicable disease between sub-Saharan black and European white patients.

Yu YL, An DW, Chori BS, Kaleta BP, Mokwatsi G, Martens DS, Abiodun OO, Anya T, Łebek-Szatańska A, Yeh JS, Mels CMC, Latosinska A, Kruger R, Isiguzo G, Narkiewicz K, Shehu MN, Salazar M, Espeche W, Mujaj B, Brgulian-Hitij J, Olszanecka A, Wojciechowska W, Reyskens P, Rajzer M, Januszewicz A, Stolarz-Skrzypek K, Asayama K, Allegaert K, Verhamme P, Mischak H, Nawrot TS, Odili AN, Staessen JA; the UPRIGHT-HTM investigators.

J Hypertens. 2025 Mar 1;43(3):481-491. doi: 10.1097/HJH.0000000000003930.

96.

Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY study.

Wasehuus V, Rotbain Curovic V, Tofte N, Lindhardt M, Currie G, Delles C, Frimodt-Møller M, Mischak H, von der Leyen H, Hansen TW, Kümler T, Persson F, Rossing P; PRIORITY Study group.

Diabetes Obes Metab. 2025 Jan;27(1):387-393. doi: 10.1111/dom.16037.

95.

Systems Biology and Novel Biomarkers for the Early Detection of Diabetic Kidney Disease.

Villalvazo P, Villavicencio C, Gonzalez de Rivera M, Fernandez-Fernandez B, Ortiz A.

Nephron. 2025;149(1):29-35. doi: 10.1159/000540307.

94.

Personalized Antifibrotic Therapy in CKD Progression.

Delrue C, Eisenga MF, Delanghe JR, Speeckaert MM.

J Pers Med. 2024 Dec 5;14(12):1141. doi: 10.3390/jpm14121141.

93.

Impact of Renal Denervation on Urinary Peptide-Based Biomarkers in Hypertension.

Lauder L, Siwy J, Mavrogeorgis E, Keller F, Kunz M, Wachter A, Emrich IE, Böhm M, Mischak H, Mahfoud F.

Hypertension. 2024 Jun;81(6):1374-1382. doi: 10.1161/HYPERTENSIONAHA.124.22819.

92.

Urinary peptide analysis to predict the response to blood pressure medication.

Jaimes Campos MA, Mavrogeorgis E, Latosinska A, Eder S, Buchwinkler L, Mischak H, Siwy J, Rossing P, Mayer G, Jankowski J.

Nephrol Dial Transplant. 2024 Apr 26;39(5):873-883. doi: 10.1093/ndt/gfad223.

91.

Integration of Urinary Peptidome and Fecal Microbiome to Explore Patient Clustering in Chronic Kidney Disease.

Mavrogeorgis E, Valkenburg S, Siwy J, Latosinska A, Glorieux G, Mischak H, Jankowski J.

Proteomes. 2024 Apr 1;12(2):11. doi: 10.3390/proteomes12020011.

90.

Assessment and Risk Prediction of Chronic Kidney Disease and Kidney Fibrosis Using Non-Invasive Biomarkers.

Rupprecht H, Catanese L, Amann K, Hengel FE, Huber TB, Latosinska A, Lindenmeyer MT, Mischak H, Siwy J, Wendt R, Beige J.

Int J Mol Sci. 2024 Mar 26;25(7):3678. doi: 10.3390/ijms25073678.

89.

Non-Invasive Biomarkers for Diagnosis, Risk Prediction, and Therapy Guidance of Glomerular Kidney Diseases: A Comprehensive Review.

Catanese L, Rupprecht H, Huber TB, Lindenmeyer MT, Hengel FE, Amann K, Wendt R, Siwy J, Mischak H, Beige J.

Int J Mol Sci. 2024 Mar 20;25(6):3519. doi: 10.3390/ijms25063519.

88.

Urinary peptidomic liquid biopsy for non-invasive differential diagnosis of chronic kidney disease.

Mavrogeorgis E, He T, Mischak H, Latosinska A, Vlahou A, Schanstra JP, Catanese L, Amann K, Huber TB, Beige J, Rupprecht HD, Siwy J.

Nephrol Dial Transplant. 2024 Feb 28;39(3):453-462. doi: 10.1093/ndt/gfad200.

87.

Differentiating primary and secondary FSGS using non-invasive urine biomarkers.

Catanese L, Siwy J, Wendt R, Amann K, Beige J, Hendry B, Mischak H, Mullen W, Paterson I, Schiffer M, Wolf M, Rupprecht H.

Clin Kidney J. 2023 Dec 4;17(2):sfad296. doi: 10.1093/ckj/sfad296.

86.

Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy.

Peters B, Beige J, Siwy J, Rudnicki M, Wendt R, Ortiz A, Sanz AB, Mischak H, Reich HN, Nasic S, Mahmood D, Persson A, Fernström A, Weiner M, Stegmayr B; PersTIgAN Working Group.

Nephrol Dial Transplant. 2023 Nov 30;38(12):2826-2834. doi: 10.1093/ndt/gfad125.

85.

Prognosis and Personalized In Silico Prediction of Treatment Efficacy in Cardiovascular and Chronic Kidney Disease: A Proof-of-Concept Study.

Jaimes Campos MA, Andújar I, Keller F, Mayer G, Rossing P, Staessen JA, Delles C, Beige J, Glorieux G, Clark AL, Mullen W, Schanstra JP, Vlahou A, Rossing K, Peter K, Ortiz A, Campbell A, Persson F, Latosinska A, Mischak H, Siwy J, Jankowski J.

Pharmaceuticals (Basel). 2023 Sep 14;16(9):1298. doi: 10.3390/ph16091298.

84.

Urine Peptidome Analysis Identifies Common and Stage-Specific Markers in Early Versus Advanced CKD.

Hobson S, Mavrogeorgis E, He T, Siwy J, Ebert T, Kublickiene K, Stenvinkel P, Mischak H.

Proteomes. 2023 Aug 23;11(3):25. doi: 10.3390/proteomes11030025.

83.

Recent Advances in Urinary Peptide and Proteomic Biomarkers in Chronic Kidney Disease: A Systematic Review.

Catanese L, Siwy J, Mischak H, Wendt R, Beige J, Rupprecht H.

Int J Mol Sci. 2023 May 23;24(11):9156. doi: 10.3390/ijms24119156.

82.

Cardiovascular risk and kidney function profiling using conventional and novel biomarkers in young adults: the African-PREDICT study.

Degenaar A, Jacobs A, Kruger R, Delles C, Mischak H, Mels C.

BMC Nephrol. 2023 Apr 13;24(1):96. doi: 10.1186/s12882-023-03100-w.

81.

Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria - A post-hoc analysis of the PRIORITY randomized clinical trial.

Rotbain Curovic V, Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Hansen TW, Havrdova T, Kooy A, Laverman GD, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Petrie JR, Ruggenenti PL, Rutters F, Rychlík I, Siwy J, Spasovski G, Speeckaert M, Trillini M, Zürbig P, von der Leyen H, Rossing P; on the behalf of the PRIORITY Study Group.

J Diabetes Complications. 2023 Apr;37(4):108433. doi: 10.1016/j.jdiacomp.2023.108433.

80.

Glycosylation Analysis of Urinary Peptidome Highlights IGF2 Glycopeptides in Association with CKD.

Lohia S, Latosinska A, Zoidakis J, Makridakis M, Mischak H, Glorieux G, Vlahou A, Jankowski V.

Int J Mol Sci. 2023 Mar 11;24(6):5402. doi: 10.3390/ijms24065402.

79.

Machine Learning-Based Urine Peptidome Analysis to Predict and Understand Mechanisms of Progression to Kidney Failure.

Massy ZA, Lambert O, Metzger M, Sedki M, Chaubet A, Breuil B, Jaafar A, Tack I, Nguyen-Khoa T, Alves M, Siwy J, Mischak H, Verbeke F, Glorieux G, Herpe YE, Schanstra JP, Stengel B, Klein J; CKD-REIN study group.

Kidney Int Rep. 2022 Dec 12;8(3):544-555. doi: 10.1016/j.ekir.2022.11.023.

78.

Association of the chronic kidney disease urinary proteomic predictor CKD273 with clinical risk factors of graft failure in kidney allograft recipients.

Rambabova-Bushljetik I, Metzger J, Siwy J, Dohcev S, Bushljetikj O, Filipce V, Trajceska L, Mischak H, Spasovski G.

Nephrol Dial Transplant. 2022 Sep 22;37(10):2014-2021. doi: 10.1093/ndt/gfab297.

77.

Urine peptidome in combination with transcriptomics analysis highlights MMP7, MMP14 and PCSK5 for further investigation in chronic kidney disease.

Petra E, Siwy J, Vlahou A, Jankowski J.

PLoS One. 2022 Jan 19;17(1):e0262667. doi: 10.1371/journal.pone.0262667.

76.

Increased Collagen Turnover Is a Feature of Fibromuscular Dysplasia and Associated With Hypertrophic Radial Remodeling: A Pilot, Urine Proteomic Study.

Latosinska A, Bruno RM, Pappaccogli M, Bacca A, Beauloye C, Boutouyrie P, Khettab H, Staessen JA, Taddei S, Toubiana L, Vikkula M, Mischak H, Persu A.

Hypertension. 2022 Jan;79(1):93-103. doi: 10.1161/HYPERTENSIONAHA.121.18146.

75.

Urine proteomics for prediction of disease progression in patients with IgA nephropathy.

Rudnicki M, Siwy J, Wendt R, Lipphardt M, Koziolek MJ, Maixnerova D, Peters B, Kerschbaum J, Leierer J, Neprasova M, Banasik M, Sanz AB, Perez-Gomez MV, Ortiz A, Stegmayr B, Tesar V, Mischak H, Beige J, Reich HN; PERSTIGAN working group.

Nephrol Dial Transplant. 2021 Dec 31;37(1):42-52. doi: 10.1093/ndt/gfaa307.

74.

Collagen-Derived Peptides in CKD: A Link to Fibrosis.

Mavrogeorgis E, Mischak H, Latosinska A, Vlahou A, Schanstra JP, Siwy J, Jankowski V, Beige J, Jankowski J.

Toxins (Basel). 2021 Dec 23;14(1):10. doi: 10.3390/toxins14010010.

73.

Reproducibility Evaluation of Urinary Peptide Detection Using CE-MS.

Mavrogeorgis E, Mischak H, Latosinska A, Siwy J, Jankowski V, Jankowski J.

Molecules. 2021 Nov 30;26(23):7260. doi: 10.3390/molecules26237260.

72.

The Use of 'Omics for Diagnosing and Predicting Progression of Chronic Kidney Disease: A Scoping Review.

Govender MA, Brandenburg JT, Fabian J, Ramsay M.

Front Genet. 2021 Nov 8;12:682929. doi: 10.3389/fgene.2021.682929.

71.

Urinary proteomics combined with home blood pressure telemonitoring for health care reform trial: rational and protocol.

Thijs L, Asayama K, Maestre GE, Hansen TW, Buyse L, Wei DM, Melgarejo JD, Brguljan-Hitij J, Cheng HM, de Souza F, Gilis-Malinowska N, Kawecka-Jaszcz K, Mels C, Mokwatsi G, Muxfeldt ES, Narkiewicz K, Odili AN, Rajzer M, Schutte AE, Stolarz-Skrzypek K, Tsai YW, Vanassche T, Vanholder R, Zhang ZY, Verhamme P, Kruger R, Mischak H, Staessen JA; UPRIGHT-HTM Investigators; Coordinating, Logistic; Recruiting, and; Urinary Proteomics Centres,; Advisors.

Blood Press. 2021 Oct;30(5):269-281. doi: 10.1080/08037051.2021.1952061.

70.

Urine peptidome analysis in cardiorenal syndrome reflects molecular processes.

Petra E, He T, Lygirou V, Latosinska A, Mischak H, Vlahou A, Jankowski 

J.Sci Rep. 2021 Aug 10;11(1):16219. doi: 10.1038/s41598-021-95695-z.

69.

Proteomic Biomarkers in the Cardiorenal Syndrome: Toward Deciphering Molecular Pathophysiology.

He T, Zhang Z, Staessen JA, Mischak H, Latosinska A, Beige J.

Am J Hypertens. 2021 Aug 9;34(7):669-679. doi: 10.1093/ajh/hpaa201.

68.

A Novel Urinary Proteomics Classifier for Non-Invasive Evaluation of Interstitial Fibrosis and Tubular Atrophy in Chronic Kidney Disease.

Catanese L, Siwy J, Mavrogeorgis E, Amann K, Mischak H, Beige J, Rupprecht H.

Proteomes. 2021 Jul 13;9(3):32. doi: 10.3390/proteomes9030032.

67.

The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease.

Verbeke F, Siwy J, Van Biesen W, Mischak H, Pletinck A, Schepers E, Neirynck N, Magalhães P, Pejchinovski M, Pontillo C, Lichtinghagen R, Brand K, Vlahou A, De Bacquer D, Glorieux G.

Nephrol Dial Transplant. 2021 Apr 26;36(5):811-818. doi: 10.1093/ndt/gfz242.

66.

Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study.

Tailliar M, Schanstra JP, Dierckx T, Breuil B, Hanouna G, Charles N, Bascands JL, Dussol B, Vazi A, Chiche L, Siwy J, Faguer S, Daniel L, Daugas E, Jourde-Chiche N, On Behalf Of The Groupe Coopératif Sur le Lupus Rénal Gclr.

J Clin Med. 2021 Apr 14;10(8):1690. doi: 10.3390/jcm10081690.

65.

Understanding glomerular diseases through proteomics.

Mavrogeorgis E, Mischak H, Beige J, Latosinska A, Siwy J.

Expert Rev Proteomics. 2021 Feb;18(2):137-157. doi: 10.1080/14789450.2021.1908893.

64.

Value of Urine Peptides in Assessing Kidney and Cardiovascular Disease.

Latosinska A, Siwy J, Faguer S, Beige J, Mischak H, Schanstra JP.

Proteomics Clin Appl. 2021 Jan;15(1):e2000027. doi: 10.1002/prca.202000027.

63.

Peptides in Plasma, Urine, and Dialysate: Toward Unravelling Renal Peptide Handling.

He T, Pejchinovski M, Mullen W, Beige J, Mischak H, Jankowski V.

Proteomics Clin Appl. 2021 Jan;15(1):e2000029. doi: 10.1002/prca.202000029.

62.

Früherkennung mittels Urinproteomanalyse: Ein neues Konzept im Patientenmanagement der diabetischen Nephropathie.

Beige J, Drube J, von der Leyen H, Pape L, Rupprecht H.

Internist (Berl). 2020 Oct;61(10):1094-1105. doi: 10.1007/s00108-020-00863-4.

61.

A single-center study to evaluate the efficacy of a fetal urine peptide signature predicting postnatal renal outcome in fetuses with posterior urethral valves.

Buffin-Meyer B, Tkaczyk M, Stańczyk M, Breuil B, Siwy J, Szaflik K, Talar T, Wojtera J, Krzeszowski W, Decramer S, Klein J, Schanstra JP.

Pediatr Nephrol. 2020 Mar;35(3):469-475. doi: 10.1007/s00467-019-04390-9.

60.

Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy.

Siwy J, Ahonen L, Magalhães P, Frantzi M, Rossing P.

Methods Mol Biol. 2020;2067:287-306. doi: 10.1007/978-1-4939-9841-8_18.

59.

Emerging urine-based proteomic biomarkers as valuable tools in the management of chronic kidney disease.

Zürbig P, Siwy J, Mischak H.

Expert Rev Mol Diagn. 2019 Oct;19(10):853-856. doi: 10.1080/14737159.2019.1657406. Epub 2019 Aug 21.

58.

Proteomics and personalized medicine: a focus on kidney disease.

Siwy J, Mischak H, Zürbig P.

Expert Rev Proteomics. 2019 Sep;16(9):773-782. doi: 10.1080/14789450.2019.1659138. Epub 2019 Aug 23.

57.

Urinary peptidomic biomarkers of renal function in heart transplant recipients.

Huang QF, Zhang ZY, Van Keer J, Trenson S, Nkuipou-Kenfack E, Yang WY, Thijs L, Vanhaecke J, Van Aelst LNL, Van Cleemput J, Janssens S, Verhamme P, Mischak H, Staessen JA.

Nephrol Dial Transplant. 2019 Aug 1;34(8):1336-1343. doi: 10.1093/ndt/gfy185.

56.

Nonproteinuric progressive diabetic kidney disease.

Zoccali C, Mallamaci F.

Curr Opin Nephrol Hypertens. 2019 May;28(3):227-232. doi: 10.1097/MNH.0000000000000489.

55.

Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial.

Siwy J, Klein T, Rosler M, von Eynatten M.

Proteomics Clin Appl. 2019 Mar;13(2):e1800144. doi: 10.1002/prca.201800144.

54.

Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease.

Cañadas-Garre M, Anderson K, McGoldrick J, Maxwell AP, McKnight AJ.

J Proteomics. 2019 Feb 20;193:93-122. doi: 10.1016/j.jprot.2018.09.020.

53.

Urinary proteome signature of Renal Cysts and Diabetes syndrome in children.

Ricci P, Magalhães P, Krochmal M, Pejchinovski M, Daina E, Caruso MR, Goea L, Belczacka I, Remuzzi G, Umbhauer M, Drube J, Pape L, Mischak H, Decramer S, Schaefer F, Schanstra JP, Cereghini S, Zürbig P.

Sci Rep. 2019 Feb 18;9(1):2225. doi: 10.1038/s41598-019-38713-5.

52.

Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease.

Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, Zürbig P, Mischak H, Ortiz A.

Sci Rep. 2018 Oct 29;8(1):15940. doi: 10.1038/s41598-018-34386-8.

51.

Kidney protective effects of baroreflex activation therapy in patients with resistant hypertension.

Wallbach M, Zürbig P, Dihazi H, Müller GA, Wachter R, Beige J, Koziolek MJ, Mischak H.

J Clin Hypertens (Greenwich). 2018 Oct;20(10):1519-1526. doi: 10.1111/jch.13365.

50.

Urinary peptide biomarker panel associated with an improvement in estimated glomerular filtration rate in chronic kidney disease patients.

Markoska K, Pejchinovski M, Pontillo C, Zürbig P, Jacobs L, Smith A, Masin-Spasovska J, Stojceva-Taneva O, Polenakovic M, Magni F, Mischak H, Spasovski G.

Nephrol Dial Transplant. 2018 May 1;33(5):751-759. doi: 10.1093/ndt/gfx263.

49.

Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion.

Critselis E, Vlahou A, Stel VS, Morton RL.

Nephrol Dial Transplant. 2018 Mar 1;33(3):441-449. doi: 10.1093/ndt/gfx068.

48.

Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.

Lindhardt M, Persson F, Oxlund C, Jacobsen IA, Zürbig P, Mischak H, Rossing P, Heerspink HJL.

Nephrol Dial Transplant. 2018 Feb 1;33(2):296-303. doi: 10.1093/ndt/gfw406.

47.

Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?

Magalhães P, Pejchinovski M, Markoska K, Banasik M, Klinger M, Švec-Billá D, Rychlík I, Rroji M, Restivo A, Capasso G, Bob F, Schiller A, Ortiz A, Perez-Gomez MV, Cannata P, Sanchez-Niño MD, Naumovic R, Brkovic V, Polenakovic M, Mullen W, Vlahou A, Zürbig P, Pape L, Ferrario F, Denis C, Spasovski G, Mischak H, Schanstra JP.

Sci Rep. 2017 Dec 5;7(1):16915. doi: 10.1038/s41598-017-17083-w.

46.

Clinical Proteomics in Kidney Disease: From Discovery to Clinical Application.

Pejchinovski M, Mischak H.

Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Dec 1;38(3):39-54. doi: 10.2478/prilozi-2018-0005.

45.

Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis.

Siwy J, Zürbig P, Argiles A, Beige J, Haubitz M, Jankowski J, Julian BA, Linde PG, Marx D, Mischak H, Mullen W, Novak J, Ortiz A, Persson F, Pontillo C, Rossing P, Rupprecht H, Schanstra JP, Vlahou A, Vanholder R.

Nephrol Dial Transplant. 2017 Dec 1;32(12):2079-2089. doi: 10.1093/ndt/gfw337.

44.

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker.

Pontillo C, Zhang ZY, Schanstra JP, Jacobs L, Zürbig P, Thijs L, Ramírez-Torres A, Heerspink HJL, Lindhardt M, Klein R, Orchard T, Porta M, Bilous RW, Charturvedi N, Rossing P, Vlahou A, Schepers E, Glorieux G, Mullen W, Delles C, Verhamme P, Vanholder R, Staessen JA, Mischak H, Jankowski J.

Kidney Int Rep. 2017 Nov;2(6):1066-1075. doi: 10.1016/j.ekir.2017.06.004.

43.

Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.

Lindhardt M, Persson F, Zürbig P, Stalmach A, Mischak H, de Zeeuw D, Lambers Heerspink H, Klein R, Orchard T, Porta M, Fuller J, Bilous R, Chaturvedi N, Parving HH, Rossing P.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1866-1873. doi: 10.1093/ndt/gfw292.

42.

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome.

Cherney D, Perkins BA, Lytvyn Y, Heerspink H, Rodríguez-Ortiz ME, Mischak H.

PLoS One. 2017 Oct 30;12(10):e0186910. doi: 10.1371/journal.pone.0186910.

41.

A Urinary Fragment of Mucin-1 Subunit α Is a Novel Biomarker Associated With Renal Dysfunction in the General Population.

Zhang ZY, Ravassa S, Pejchinovski M, Yang WY, Zürbig P, López B, Wei FF, Thijs L, Jacobs L, González A, Voigt JU, Verhamme P, Kuznetsova T, Díez J, Mischak H, Staessen JA.

Kidney Int Rep. 2017 Sep;2(5):811-820. doi: 10.1016/j.ekir.2017.03.012.

40.

A urinary proteome-based classifier for the early detection of decline in glomerular filtration.

Pontillo C, Jacobs L, Staessen JA, Schanstra JP, Rossing P, Heerspink HJL, Siwy J, Mullen W, Vlahou A, Mischak H, Vanholder R, Zürbig P, Jankowski J.

Nephrol Dial Transplant. 2017 Sep 1;32(9):1510-1516. doi: 10.1093/ndt/gfw239.

39.

The long path towards implementation of clinical proteomics: Exemplified based on CKD273.

Nkuipou-Kenfack E, Zürbig P, Mischak H.

Proteomics Clin Appl. 2017 May;11(5-6). doi: 10.1002/prca.201600104.

38.

Clinical proteomics in kidney disease as an exponential technology: heading towards the disruptive phase.

Sanchez-Niño MD, Sanz AB, Ramos AM, Fernandez-Fernandez B, Ortiz A.

Clin Kidney J. 2017 Apr;10(2):188-191. doi: 10.1093/ckj/sfx023.

37.

Proteomanalyse: Neue Wege zur verbesserten Behandlung der diabetischen Nephropathie.

Drube J, Zürbig P, Beige J, Mischak H, Jankowski J.

Diabetologie und Stoffwechsel 2017 Apr;12(03):213-221. doi: 10.1055/s-0043-106192.

36.

Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease.

Pontillo C, Mischak H.

Clin Kidney J. 2017 Apr;10(2):192-201. doi: 10.1093/ckj/sfx002.

35.

PeptiCKDdb-peptide- and protein-centric database for the investigation of genesis and progression of chronic kidney disease.

Krochmal M, Fernandes M, Filip S, Pontillo C, Husi H, Zoidakis J, Mischak H, Vlahou A, Jankowski J.

Database (Oxford). 2016 Sep 1;2016:baw128. doi: 10.1093/database/baw128. 

34.

Urinary biomarkers to predict CKD: is the future in multi-marker panels?

Pontillo C, Mischak H.

Nephrol Dial Transplant. 2016 Sep;31(9):1373-5. doi: 10.1093/ndt/gfv467.

33.

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial.

Lindhardt M, Persson F, Currie G, Pontillo C, Beige J, Delles C, von der Leyen H, Mischak H, Navis G, Noutsou M, Ortiz A, Ruggenenti PL, Rychlik I, Spasovski G, Rossing P.

BMJ Open. 2016 Mar 2;6(3):e010310. doi: 10.1136/bmjopen-2015-010310.

32.

The role of urinary peptidomics in kidney disease research.

Klein J, Bascands JL, Mischak H, Schanstra JP.

Kidney Int. 2016 Mar;89(3):539-45. doi: 10.1016/j.kint.2015.10.010.

31.

Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression.

Critselis E, Lambers Heerspink H.

Nephrol Dial Transplant. 2016 Feb;31(2):249-54. doi: 10.1093/ndt/gfv062.

30.

Urinary proteomics in chronic kidney disease: diagnosis and risk of progression beyond albuminuria.

Øvrehus MA, Zürbig P, Vikse BE, Hallan SI.

Clin Proteomics. 2015 Aug 7;12(1):21. doi: 10.1186/s12014-015-9092-7.

29.

Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes.

Pena MJ, de Zeeuw D, Mischak H, Jankowski J, Oberbauer R, Woloszczuk W, Benner J, Dallmann G, Mayer B, Mayer G, Rossing P, Lambers Heerspink HJ.

Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv86-95. doi: 10.1093/ndt/gfv252.

28.

Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.

Schanstra JP, Zürbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R.

J Am Soc Nephrol. 2015 Aug;26(8):1999-2010. doi: 10.1681/ASN.2014050423.

27.

Comparison of Depletion Strategies for the Enrichment of Low-Abundance Proteins in Urine.

Filip S, Vougas K, Zoidakis J, Latosinska A, Mullen W, Spasovski G, Mischak H, Vlahou A, Jankowski J.

PLoS One. 2015 Jul 24;10(7):e0133773. doi: 10.1371/journal.pone.0133773.

26.

Proteomic urinary biomarker approach in renal disease: from discovery to implementation.

Schanstra JP, Mischak H.

Pediatr Nephrol. 2015 May;30(5):713-25. doi: 10.1007/s00467-014-2790-y.

25.

Pro: urine proteomics as a liquid kidney biopsy: no more kidney punctures!

Mischak H.

Nephrol Dial Transplant. 2015 Apr;30(4):532-7. doi: 10.1093/ndt/gfv046.

24.

Impact of a 6-wk olive oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery disease, chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled, double-blind study.

Silva S, Bronze MR, Figueira ME, Siwy J, Mischak H, Combet E, Mullen W.

Am J Clin Nutr. 2015 Jan;101(1):44-54. doi: 10.3945/ajcn.114.094219.

23.

The urinary proteome as correlate and predictor of renal function in a population study.

Gu YM, Thijs L, Liu YP, Zhang Z, Jacobs L, Koeck T, Zürbig P, Lichtinghagen R, Brand K, Kuznetsova T, Olivi L, Verhamme P, Delles C, Mischak H, Staessen JA.

Nephrol Dial Transplant. 2014 Dec;29(12):2260-8. doi: 10.1093/ndt/gfu234.

22.

Urinary proteomics and molecular determinants of chronic kidney disease: possible link to proteases.

Filip S, Pontillo C, Peter Schanstra J, Vlahou A, Mischak H, Klein J.

Expert Rev Proteomics. 2014 Oct;11(5):535-48. doi: 10.1586/14789450.2014.926224.

21.

Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy.

Siwy J, Schanstra JP, Argiles A, Bakker SJ, Beige J, Boucek P, Brand K, Delles C, Duranton F, Fernandez-Fernandez B, Jankowski ML, Al Khatib M, Kunt T, Lajer M, Lichtinghagen R, Lindhardt M, Maahs DM, Mischak H, Mullen W, Navis G, Noutsou M, Ortiz A, Persson F, Petrie JR, Roob JM, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Snell-Bergeon J, Spasovski G, Stojceva-Taneva O, Trillini M, von der Leyen H, Winklhofer-Roob BM, Zürbig P, Jankowski J.

Nephrol Dial Transplant. 2014 Aug;29(8):1563-70. doi: 10.1093/ndt/gfu039.

20.

Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease.

Nkuipou-Kenfack E, Duranton F, Gayrard N, Argilés À, Lundin U, Weinberger KM, Dakna M, Delles C, Mullen W, Husi H, Klein J, Koeck T, Zürbig P, Mischak H.

PLoS One. 2014 May 9;9(5):e96955. doi: 10.1371/journal.pone.0096955.

19.

Fetal urinary peptides to predict postnatal outcome of renal disease in fetuses with posterior urethral valves (PUV).

Klein J, Lacroix C, Caubet C, Siwy J, Zürbig P, Dakna M, Muller F, Breuil B, Stalmach A, Mullen W, Mischak H, Bandin F, Monsarrat B, Bascands JL, Decramer S, Schanstra JP.

Sci Transl Med. 2013 Aug 14;5(198):198ra106. doi: 10.1126/scitranslmed.3005807.

18.

CKD273, a new proteomics classifier assessing CKD and its prognosis.

Argilés Á, Siwy J, Duranton F, Gayrard N, Dakna M, Lundin U, Osaba L, Delles C, Mourad G, Weinberger KM, Mischak H.

PLoS One. 2013 May 14;8(5):e62837. doi: 10.1371/journal.pone.0062837.

17.

Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience.

Mischak H, Vlahou A, Ioannidis JP.

Clin Biochem. 2013 Apr;46(6):432-43. doi: 10.1016/j.clinbiochem.2012.09.025.

16.

Urinary proteomics for early diagnosis in diabetic nephropathy.

Zürbig P, Jerums G, Hovind P, Macisaac RJ, Mischak H, Nielsen SE, Panagiotopoulos S, Persson F, Rossing P.

Diabetes. 2012 Dec;61(12):3304-13. doi: 10.2337/db12-0348.

15.

A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases.

Molin L, Seraglia R, Lapolla A, Ragazzi E, Gonzalez J, Vlahou A, Schanstra JP, Albalat A, Dakna M, Siwy J, Jankowski J, Bitsika V, Mischak H, Zürbig P, Traldi P.

J Proteomics. 2012 Oct 22;75(18):5888-97. doi: 10.1016/j.jprot.2012.07.024.

14.

Urinary proteomics in the assessment of chronic kidney disease.

Mullen W, Delles C, Mischak H; EuroKUP COST action.

Curr Opin Nephrol Hypertens. 2011 Nov;20(6):654-61. doi: 10.1097/MNH.0b013e32834b7ffa.

13.

Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury.

Metzger J, Kirsch T, Schiffer E, Ulger P, Mentes E, Brand K, Weissinger EM, Haubitz M, Mischak H, Herget-Rosenthal S.

Kidney Int. 2010 Dec;78(12):1252-62. doi: 10.1038/ki.2010.322.

12.

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.

Andersen S, Mischak H, Zürbig P, Parving HH, Rossing P.

BMC Nephrol. 2010 Nov 1;11:29. doi: 10.1186/1471-2369-11-29.

11.

Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease.

Good DM, Zürbig P, Argilés A, Bauer HW, Behrens G, Coon JJ, Dakna M, Decramer S, Delles C, Dominiczak AF, Ehrich JH, Eitner F, Fliser D, Frommberger M, Ganser A, Girolami MA, Golovko I, Gwinner W, Haubitz M, Herget-Rosenthal S, Jankowski J, Jahn H, Jerums G, Julian BA, Kellmann M, Kliem V, Kolch W, Krolewski AS, Luppi M, Massy Z, Melter M, Neusüss C, Novak J, Peter K, Rossing K, Rupprecht H, Schanstra JP, Schiffer E, Stolzenburg JU, Tarnow L, Theodorescu D, Thongboonkerd V, Vanholder R, Weissinger EM, Mischak H, Schmitt-Kopplin P.

Mol Cell Proteomics. 2010 Nov;9(11):2424-37. doi: 10.1074/mcp.M110.001917.

10.

Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease.

Caubet C, Lacroix C, Decramer S, Drube J, Ehrich JH, Mischak H, Bascands JL, Schanstra JP.

Pediatr Nephrol. 2010 Jan;25(1):27-35. doi: 10.1007/s00467-009-1251-5.

9.

Proteomics in uremia and renal disease.

Mischak H, Massy ZA, Jankowski J.

Semin Dial. 2009 Jul-Aug;22(4):409-16. doi: 10.1111/j.1525-139X.2009.00591.x.

8.

The role of EUTox in uremic toxin research.

Vanholder R, Abou-Deif O, Argiles A, Baurmeister U, Beige J, Brouckaert P, Brunet P, Cohen G, De Deyn PP, Drüeke TB, Fliser D, Glorieux G, Herget-Rosenthal S, Hörl WH, Jankowski J, Jörres A, Massy ZA, Mischak H, Perna AF, Rodriguez-Portillo JM, Spasovski G, Stegmayr BG, Stenvinkel P, Thornalley PJ, Wanner C, Wiecek A.

Semin Dial. 2009 Jul-Aug;22(4):323-8. doi: 10.1111/j.1525-139X.2009.00574.x.

7.

The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease.

Zürbig P, Decramer S, Dakna M, Jantos J, Good DM, Coon JJ, Bandin F, Mischak H, Bascands JL, Schanstra JP.

Proteomics. 2009 Apr;9(8):2108-17. doi: 10.1002/pmic.200800560.

6.

Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease.

Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K, Delles C, Mischak H, Metzger J.

J Proteome Res. 2009 Jan;8(1):268-81. doi: 10.1021/pr800401m.

5.

Urinary proteomics in diabetes and CKD.

Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, Good DM, Coon JJ, Tarnow L, Rossing P; PREDICTIONS Network.

J Am Soc Nephrol. 2008 Jul;19(7):1283-90. doi: 10.1681/ASN.2007091025.

4.

Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases.

Julian BA, Wittke S, Novak J, Good DM, Coon JJ, Kellmann M, Zürbig P, Schiffer E, Haubitz M, Moldoveanu Z, Calcatera SM, Wyatt RJ, Sýkora J, Sládková E, Hes O, Mischak H, McGuire BM.

Electrophoresis. 2007 Dec;28(23):4469-83. doi: 10.1002/elps.200700237.

3.

Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases.

Julian BA, Wittke S, Haubitz M, Zürbig P, Schiffer E, McGuire BM, Wyatt RJ, Novak J.

World J Urol. 2007 Oct;25(5):467-76. doi: 10.1007/s00345-007-0192-5.

2.

Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease.

Chalmers MJ, Mackay CL, Hendrickson CL, Wittke S, Walden M, Mischak H, Fliser D, Just I, Marshall AG.

Anal Chem. 2005 Nov 15;77(22):7163-71. doi: 10.1021/ac050983o.

1.

Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy.

Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, Haller H, Mischak H.

Kidney Int. 2005 Jun;67(6):2313-20. doi: 10.1111/j.1523-1755.2005.00335.x.